Start

In this first study of its kind in men with erectile dysfunction who had not previously been treated with a phosphodiesterase type 5 (PDE5) inhibitor, 81% of men who took Levitra (vardenafil) reported improved erections (81% with Levitra vs 30% who took a placebo; p<0.0001). 78% of men were able to maintain their erections to complete intercourse (known as SEP3, 78% with Levitra vs 41% with placebo, p<0.0001). Levitra is a couple’s solution, couples reported that the man’s treatment with Levitra significantly improved confidence (64% vs 41% for men; 60% vs 37% for partners), pleasure (67% vs 44% for men; 64% vs 38% for partners) and satisfaction with erection (60% vs 28% for men; 58% vs 27% for partners), orgasm (60% vs 32% for men; 56% vs 32% for partners) and with Levitra itself (62% vs 31% for men; 58% vs 30% for partners; all p<0.0001).

This 12-week, multicentre, randomised, double-blind, placebo-controlled study involved 260 men aged 18 years or older with ED for more than 6 months. The starting dose of vardenafil was 10 mg, which could be titrated to 5 mg or 20 mg. Two of the primary endpoints were response to the Global Assessment Question (GAQ, ‘Has the treatment you have been taking improved your erections?’) and positive response to SEP3 “Did you maintain your erection long enough to complete intercourse?”. The secondary efficacy measure included men and partners responses to questions on the Treatment Satisfaction Scale (TSS)

End

This entry was posted on Monday, August 11th, 2008 at 9:55 am and is filed under General Information. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.